News | Radiopharmaceuticals and Tracers | December 28, 2016

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmacopeia (USP) recommendations for compounded sterile radiopharmaceuticals. The recommendations aim to address certain common practices in the field of nuclear pharmacy that are not adequately defined by generally accepted practice standards. The society believes there is confusion in the field of nuclear pharmacy, which threatens the availability and the safe usage of radiopharmaceuticals in the United States. The recommendations are a response to these challenges.

The recommendations were developed by SNMMI's Committee on Radiopharmaceuticals (COR) and approved by SNMMI's Board of Directors. The COR worked with several professional organizations and trade associations in an attempt to rectify the situation. Our efforts to date have met with some success, but have still fallen short of realizing suitable standards that are generally accepted for common practices in nuclear pharmacy. The COR believes that the USP, as the world’s leading organization for the development and maintenance of public standards, can play a critical role in the resolution of these challenges.

There are three recommendations detailed in a SNMMI white paper: 

1. Establish an expert panel to delineate common practices that are defined as sterile compounding within the practice of nuclear pharmacy.
2. Create a public standard for the preparation, compounding, and dispensing of sterile radiopharmaceuticals with the practice of nuclear pharmacy.
3. Reinstate an expert committee dedicated to all standards for radiopharmaceuticals.

On September 29, SNMMI President Sally Schwarz sent the letter to the USP, where it is currently under consideration. Further details will be provided as they become available.

Access the complete document at http://snmmi.files.cms-plus.com/SNMMI-USP-Recommendations-Final_2016.pdf


Related Content

News | Radiopharmaceuticals and Tracers

March 27, 2025 — GE HealthCare is announcing the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the 2025 ...

Home March 25, 2025
Home
News | Radiopharmaceuticals and Tracers

April 13, 2023 — A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin ...

Home April 13, 2023
Home
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Home November 05, 2022
Home
News | Radiopharmaceuticals and Tracers

June 24, 2022 — Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive ...

Home June 24, 2022
Home
News | Radiopharmaceuticals and Tracers

August 2, 2019 — The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) ...

Home August 02, 2019
Home
News | Radiopharmaceuticals and Tracers

July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot ...

Home July 16, 2019
Home
News | Radiopharmaceuticals and Tracers

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel ...

Home June 05, 2019
Home
News | Radiopharmaceuticals and Tracers

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular ...

Home May 17, 2019
Home
News | Radiopharmaceuticals and Tracers | Jeff Zagoudis, Associate Editor

May 10, 2019 — Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in ...

Home May 10, 2019
Home
News | Radiopharmaceuticals and Tracers

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide ...

Home October 12, 2018
Home
Subscribe Now